AstraZeneca has ceased development of its nicotinic channel blocker TC 5214 for which it had collaborated with Targacept as an...
AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with Major Depressive Disorder did not meet...
Targacept has announced top-line results from a Phase IIb clinical trial of TC 5214 as a treatment for Overactive Bladder...
A Phase II asthma study of TC 6987 from Targacept was a double blind, placebo controlled, parallel group trial conducted...
Targacept, Inc. a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, has announced top-line results from a Phase IIb monotherapy clinical...
Phase III results of TC 5214, a nicotinic channel blocker from AstraZeneca/Targacept, were disappointing in the first study (RENAISSANCE 3)...
Targacept Inc., has announced top-line results from a Phase II trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity...
This review discusses the molecular mechanisms associated to the pathogenesis of different types of TC and their clinical relevance.